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Summary.-The metabolism of [2-14C]+ [3', 5', 7, 9-3H] folic acid and [214C]+[3', 5',7,
9-3H] 10-formylfolate was studied in hospital inpatients. Metabolites detected in the
urine after folic acid feeding included the unchanged compound, other folates and a
number of breakdown products, such as p-acetamidobenzoyl-L-glutamate and
p-acetamidobenzoate. This confirms the existence of a folate catabolic pathway in
man.
Patients with malignant disease excreted less of the dose in urine, incorporated
more into the reduced folate pool, and showed decreased catabolism of folate, when
compared to controls. 10-Formylfolate was excreted largely unchanged, and appears
not to be reduced by man. Also 10-formylfolate interfered with the reduction of folic
acid given simultanteously.
EARLIER STUDIES on the metabolism of
folic acid by man, using 3H-labelled tracers
(Chanarin & McLean, 1967) or microbio-
logical assay (Ratanasthien, 1 975), yielded
conflicting results. There have been no
detailed studies since the introduction of
the unambiguous technique of using a
mixture of 14C- and 3H-labelled species by
ourselves, and the recognition of a break-
down process as a major route of meta-
bolism offolates in the rat (Murphy et al.,
1976; Connor et al., 1979).
It is believed that two pools of folate
exist in the rat; a short-term pool offolate
monoglutamates giving p-acetamido-
benzoate as a urinary catabolite, and a
long-term pool of folate polyglutamates
giving p-acetamidobenzoyl-L-glutamate
(Pheasant et al., 1981). The identification
of 14C-labelled pterins in the urine of one
human subject given 14C-folic acid
(Krumdieck et al., 1978) and 3H-p-aceta-
midobenzoyl-L-glutamate in the urine of
a limited number of subjects given 3H-
+14C-labelled folic acid (Pheasant et al.,
1979), together with the pattern of excre-
tion ofradioactivity in these experiments,
suggest that the same metabolic pools and
catabolic routes may exist in man.
Folates are essential for cell division,
and folate status is therefore important in
malignant disease. Folate deficiency is
associated with malignant disease
(Blakley, 1969; Chanarin, 1979) but no
detailed comparative metabolic studies
have been carried out in man. Catabolism
offolate in the rat has recently been shown
to be reduced in the presence of a tumour
(Saleh et al., 1981). Therefore the meta-
bolism ofa mixture of14C- and 3H-labelled
folic acid was studied in control patients
and in patients with malignant disease in
order to observe any metabolic variations
which may have diagnostic or therapeutic
applications. Preliminary results have
been reported elsewhere (Saleh et al.,
1980).
10-Formylfolate, an oxidized folate, is
an important constituent of food folate
(Butterworth et al., 1965; Santini et al.,FOLATE METABOLISM IN MALIGNANT DISEASE
1964). However, it is not reduced by
Ehlrich ascites carcinoma (Bertino et al.,
1965) or bovine dihydrofolate reductase
(A. Sahota, personal communication) and
therefore may not be available to
mammals. Earlier investigations by
Ratanasthien et al. (1974), using a micro-
biological assay, showed no metabolism of
orally administered 10-formylfolate by
man. However, Pheasant et al. (1981)
found that radiolabelled 10-formylfolate
was incorporated into the reduced folate
pool ofthe rat. Further studies undertaken
using radiolabelled 10-formylfolate in
man, to resolve these apparent discrepan-
cies, are described here.
MATERIALS AND METHODS
Experimental design
Patients.-The study was carried out on
hospital inpatients (General Hospital,
Birmingham) suffering from malignant dis-
ease or other disorders. Details ofthe patients
may be found in Table I. All patients were
allowed a normal diet throughout the experi-
ment. Informed consent was obtained from
all participants.
Metabolism of folic acid.-Two groups of
patients were used: Group I- I patients
suffering from malignant disease; Group II.-
6 patients suffering from other disorders as
controls. All patients were given an oral dose
of a mixture of 5 uCi [2-14C] folic acid and
20 ,uCi [3', 5', 7, 9-3H] folic acid plus 5 mg
unlabelledfolic acid.
Metabolism of 10-formylfolic acid and its
effect on folic acid metabolism.-Three groups
of 3 control patients were used:
Group III.-Patients were given a mixture
of [2-14C] folic acid+[3', 5', 7, 9-3H] folic acid
(60 ,tg).
Group IV.-Patients were given a mixture
of [2-14C]+[3', 5', 7, 9-3H] 10-formylfolic
acid+5 mg unlabelled 10-formylfolic acid.
Group V.-Patients were given a mixture
of [2-14C] +[3', 5', 7, 9-3H] folic acid (60 ,ug)+
5 mg unlabelled 10-formylfolic acid.
Urine andfaeces collection
Urine was collected on sodium ascorbate
(10 g) for the following periods; 0-6 h, 6-12 h
and 12-24 h after administration ofthe dose.
Urine volumes were measured for each period,
and samples kept frozen at -200C until
analysis, which was within a week of collec-
tion. In some cases faeces were collected in a
plastic bag, which was closed with a rubber
band and put into an air-tight container.
Determination ofradioactivity
Urine samples and column effluents were
counted as described in Connor et al. (1979).
Faeces were freeze-dried and ground to give
a homogeneous powder; 100mg samples were
used to estimate total radioactivity as
described by Barford et al (1978).
Chromatography
Sephadex G15 gel filtration and DEAE-
cellulose chromatography (using linear gradi-
ents of 0-1 2M NaCl in 0-05M sodium phos-
phate buffer, pH 7 0) were performed as
described previously (Barford et al., 1977).
Paper chromatography was performed as
described by Connor et al. (1979).
Chemicals
All chemicals used were of Analar grade or
its equivalent. [2-14C] Folic acid (sp. 50 mCi/
mmol) and (3', 5', 7, 9-3H] folic acid (sp. 500
mCi/mmol) were obtained from the Radio-
chemical Centre, Amersham, Bucks. p-Acet-
amidobenzoyl-L-glutamate was prepared as
described in Baker et al. (1964). 10-Formyl-
folic acid was synthesized from folic acid
(Blakley, 1959), and [2-14C] and [3', 5', 7, 9-
3H) 10-formylfolic acid was prepared as
follows: a solution of[2-14C] folic acid (50 ,uCi,
52-4 mCi/mmol) and [3', 5', 7, 9-3H] folic
acid (250 ,uCi, 500 mCi/mmol) was dissolved
in 0-8 ml of distilled formic acid (98%).
After storage of the solution in the dark at
room temperature for 48 h, the excess formic
acidwasremovedbyfreeze-drying. Chromato-
graphy of the product on DEAE-cellulose
gave a single radioactive peak at 0-53M NaCl,
co-chromatographing with authentic 10-
formylate (folic acid elutes at 0-96M NaCl).
RESULTS
Metabolism of folic acid
The urinary recoveries of radioactivity
after an oral dose of labelled folic acid
(5 mg) are shown in Table II. There is a
discrepancy between the recovery of 3H
and 14C in the urine. Urinary recovery of
3H was significantly higher than 14C in
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Group Name
N.C.
G.R.
B.B.
K.M.
H.P.
I I.G.
C.H.
L.J.
J.H.
D.M.
W.M.
rC.C.
N.R.
II S.R.
E.W.
E.T.
L.W.
rA.G.
II P.H.
LT.C.
rR.S.
IV G.L.
LA.M.
rF.C.
V S.H.
tM.F.
TABLE I.-Clinical details ofpatients studied
Age Sex Diagnosis Therapy
48 M Cancer of oesophagus None
60 M Lymphosarcoma Daunarubicin, Ara-C thioguanine
63 F Adenocarcinoma of ascending colon None
68 F Bronchial carcinoma and metastases Cyclizine-HCl, dihydrocodeine,
in thoracic spines Distalgesic
67 M Bronchial carcinoma None
75 F Cancer of breast-diabetes Morphine, Tamoxophen,
chlorpropamide
68 M Cancer of lung Radiotherapy
64 M Lymphosarcoma Radiotherapy, paracetamol
73 M Adenocarcinoma of the stomach None
17 M Lymphocytic lymphoma Prednisone, K supplements
66 M Non-Hodgkin's lymphoma Prednisone, pethidine
66 M Chronic bronchitis and emphysema Salbutamol, diuretics
67 M Hypertension Diuretics
74 M Myocardial infarction Diuretics
68 F Cervical spondylitis Dihydrocodeine
82 M Deep-vein thromosis Digoxin and diuretics
55 M Hypertension-cerebrovascular None
accident
59 M Myocardial infarction Moduretic
63 M Hypertension and possible myocardial Thiazide-Distalgesic
infarction Triazolam
56 M Anterolateral myocardial infarction None
57 M Myocardial infarction Nitrazepam
75 M Myocardial infarction Triazolam-aspirin
48 M Retroperitoneal fibrosis Paracetamol
67 F 7¶yocardial infarction Frusemide-Slow K-triazolam
72 M -I:lbar palsy None
70 F I.yocardial infarction-hypertension Moduretic
TABLEII.-Urinaryrecoveryofradioactivityafteranoraldoseof [2-14C]and[3', 5', 7, 9-3H]
folic acid (5 my). The results are expressed as the percentage of the dose recovered during
the 3 collection periods
% ofdose recovered
0-6 h 6-12 h 12-24 h 0-24 h
Patients 3H 14C 3H 14C 3H 14C 3H 14C
23-8 20-4 4-6 3-7 1-6 0-2
15-1 14-6 8-4 8-0 2-1 2-2
0-3 0-2 15-0 12-0 7-0 6-0
12-3 10-4 7 0 5-9 2-4 1-7
14-7 13-2 3-6 3-1 0-9 0-5
10-2 8-0
1-2 0-9 8-2 7-3 Died
2-5 2-4 2-4 0-8
- - 1-7 1-4 3-0 1-4
2-0 1-8 - 0-4 0-5
0-1 0-1 0 7 0-7 0-3 0-3
30-0
25-6
22-3
21 -7
19-2
4 9
4-7
2-4
1.1
24-3
24-8
18-3
18-0
16-8
3 -2
2-8
2-3
1-1
14-1+3-7* 12-4+3-3*
29-0 23-3 9-0 7-4 1-2 1-1
8-6 8-4 24-0 22-2 4-7 3-1
19-6 17-3 5-3 4-6 8-4 7-3
16-5 12-3 6-6 4-9 2-9 1-6
12-7 11-3
11-6 9-4 7-1 5-7 5-6 2-3
39-2
37-3
33 -3
26-0
31 -8
33-7
29-2
18-8
24-3 17-4
32+3-0* 26-2+3-4*
Cancer
N.C.
G.R.
B.B.
K.M.
H.P.
I.G.
C.H.
L.J.
J.H.
D.M.
W.M.
Control
C.C.
N.R.
S.R.
E.W.
L.W.
E.T.
Increasing
tumour mass
* Mean +s.e.FOLATE METABOLISM IN MALIGNANT DISEASE
TABLE III.-Faecal recovery of radio-
activity after an oral dose of [2-14C] and
[3',5', 7, 9-3H] folic acid. The results are
expressed as the percentage of the dose
recovered in 46 h
Faecal
dry weight
(g)
87 -3
60-0
38-1
4 9
%Dose recovered
3H 14C
10-8 28-0
6-7 13-9
10-3 26-6
0-2 0-3
both groups of patients, when determined
by a paired t test (P< 0-001). Cancer
patients excreted significantly less radio-
activity in urine than control patients
(P<0001); 14.1% 3H, 12.4% 140 and
32.0% 3H and 26.2% 14C ofthe dose being
excreted in the urine of cancer patients
and control patients, respectively. Most of
the radioactivity appearing in the urine
was excreted in the first 12 h by both
groups of patients. Excreted radioactivity
fell rapidly on the second day, but was
detected at low levels in the urine up to 5
days. The urinary recovery ofthe individ-
ual cancer patients showed an inverse
correlation between total urinary recovery
and size of tumour. The urinary recovery
decreased as the approximate size and ex-
tent ofthe tumour mass, as judged by the
clinician, increased, indicating a larger re-
quirement for folate in malignant disease.
Table III shows the recovery of 3H and
14C in the faeces; where more 14C than 3H
was present. No evidence for malabsorp-
tion of folate in malignant disease was
apparent from these investigations.
Urinary metabolites
Urine samples were sequentially chrom-
atographed on DEAE-cellulose, Sephadex
G15 and paper. In all cases, this revealed a
number of radioactive components. Three
of the components detected in the urine
retained the 3H- and 14C-label in the same
ratio, and were identified by co-chromato-
graphy with authentic standards in both
column systems as folic acid, 5-methyl-
TABLE IV.-Metabolites present in the urine collected 0-24 h after the feeding [2-14C]
[3', 5', 7, 9-3H] folic acid. The results are expressed as the percentage of the dose as
each metabolite.
% dose
A
Folic acid 5MeTHF pAcBG pAcBA
3H 14C 3H 14C 3H 3H
18-8
8-9
11 *6
14-1
13-1
5-8
1-1
0-1
0 7
8-2+2-2
26-3
26-2
22-1
18-2
13 -4
21 - 2 + 2 - 5
17 0
9-2
9.5
12-8
12-2
5.9
1-1
0-1
0-6
7 - 6 + 2 0
20-2
23-3
20-0
14-1
11*2
3-8
4.7
5.3
2 0
2-2
1-1
0 7
0-2
1*4
2-4+0-6
5*0
3 -3
5.7
3 -6
4-8
17-7+2-2 4*5+0*4
3.7
5 -3
4-9
2-1
1*9
1 0
0 7
0-2
1 *3
2.3+0-6
4-2
3 -3
5.5
2-7
4*0
3 9 + 0 5
0 9
2 -8
2-7
2-6
1.0
1 6
1*4
1 *6
1 *6+0-3
5
n.d.
3-2
2-2
3 -6
3 *5+0-6
0-1
0-1
0 3
0 *3
1*6
2 -2
0 5+0 3
n.d.
0 9
1 *4
0-8
0*8+0 3
5MeTHF; 5-methyltetrahydrofolate. pAcBG; p-acetamidobenzoyl-L-glutamate
pAcBA; p-acetamidobenzoate.
n.d.; not determined.
Patient
Cancer
L.J.
G.R.
Control
E.W.
E.T.
Patient
Cancer
N.C.
G.R.
B.B.
K.M.
H.P.
C.H.
L.J.
J.H.
D.M.
Mean + s.e.
Control
CC.
N.R.
S.R.
E.W.
E.T.
Mean + s.e.
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tetrahydrofolate (5MeTHF) and 10-
formylfolate. The ratio 3H/14C in these
folate derivatives was higher than in the
folic acid administered. The remaining
components detected in the urine of both
groups were catabolites, labelled solely
with 3H or mainly with 14C. The
3H-catabolites were identified as p-acet-
amidobenzoyl-L-glutamate, p-acetamido-
benzoate and water. The 14C-labelled
catabolite has not been identified. It
eluted from both columns in the position
of metabolite B which has been recently
reorted in rat urine (Saleh et al., 1981).
Table IV summarizes the relative distribu-
tion ofthe major metabolites appearing in
the various urine samples ofboth groups of
patients. Cancer patients excreted signi-
ficantly less unchanged folic acid than
control patients (0 01 <P< 0 05). There is
no significant difference in 5MeTHF excre-
tion between the two groups, but the ratio
of folic acid to 5MeTHF decreased con-
siderably with time in cancer patients,
whereas it decreased only slightly in
control patients (folic acid/5MeTHF for
0-6 h, 6-12 h, and 12-24 h; 5-2, 3 1, 1 0 for
Group I; 5-6, 5,1, 2-8 for Group II). Urin-
ary scission product excretion relative to
intact folates increased with time in both
groups. However, total scission products
were significantly decreased in cancer
patients (0.01 <P< 0.05). p-Acetamido-
benzoate was not present in 0-6h urine
samples of either group and appeared in
the 6-12h urine sample of most cancer
patients but only one control patient
(E.W.). Its excretion was maximal in the
12-24h urine samples of both groups. p-
Acetamidobenzolyl-L-glutamate showed a
reciprocal pattern: it was maximal in the
first urine samples (0-6 h) and decreased
slowly as a percentage of the dose
thereafter. Overall, p-acetamidobenzoyl-L-
glutamate excretion was significantly de-
pressed in cancer patients (P< 0.05),
whereas p-acetamidobenzoate excretion
was unchanged.
Metabolism of 10-formylfolic acid and its
effect onfolic acid metabolism
Group III: Metabolism of folic acid
(60 ,ug).-2.6% of 3H and 1.8% of 14C of
the dose were excreted in the urine in 24 h
by control subjects receiving 60 ,ug folic
acid (Table V), and 1.7% 14C and 1.3% of
3H were recovered in their faeces in 48 h.
Thus at this lower dose offolic acid a much
TABLE V.- Urinary recovery of radioactivity after oral doses offolates.
0-6 h 6-12 h 12-24 h 0-24 h
3H 14C 3H 14C 3H 14C 3H 14C
0-6
1-1
0-6
0 9
0-6
1-2
46-1 41-1
40-1 38-2
25-4 22-4 died
5-4 5.5
23 -1 22 -4
7-6 7-5
0.6
0 5
0 7
0 3 0-2
0 7 05
05 0.5
2-2 1-4
3-1 2-1
2-5 1-8
2.6 1.8
4-3 4-0 1-4 0 7 51-8 45-8
5-8 5-7 0 4 0 7 46-3 44-6
49 1 45 2
3 -2
5 -8
5 0
2-9 1-2 0-2 9-8 8-6
5-8 1-8 1-2 30 7 29-4
4-6 n.d. n.d. 12-6 12-1
17-7 16-7
Group III: [2-14C]+[3',5',7,9-3H]-folic acid (60 jig).
Group IV: [2-14C]+[3',5',7,9-3H]-1O formylfolic acid (5 mg).
Group V: [2-14C] + [3',5',7,9-3H]-folic acid (60 ,ug) + 5 mg unlabelled 10 formylfolic acid.
The results are expressed as the percentage of the dose recovered in the different collection periods.
n.d.: not determined.
1.0
1-8
0-8
Patient
Group III
A.G.
P.H.
T.C.
Mean
Group IV
R.S.
A.M.
G.L.
Mean
Group V
F.C.
S.H.
M.F.
MeanFOLATE METABOLISM IN MALIGNANT DISEASE
TABLE VI.-Metabolites present in the urine collected 12 h after the
administration of labelledfolates
Patient
Group IV*
R.R.
A.M.
G.L.t
Folic acid 5MeTHF 10-formylfolic acid
3H 14C 3H 14C 3H 14C
1-5 1-4
2-1 2-1
0-9 0-8
0-9 0-9
1.1 1-2
0.5 0-4
46-4 41-3
40-4 39-0
23-7 20-7
Group V*
M.F. 10-0 9 9 0 9 0 9 0.5 0.5
S.H. 23-8 23-2 2-3 2-3 0-6 0-7
F.C. 6-2 6-5 0-9 0.9 0-5 0-5
Mean 13-3 13-2 1-4 1-4 0-6 0-6
The results are expressed as the percentage of the dose present as each metabolite.
* As in Table V.
t 0-6 h only.
greaterproportion ofthe dose was retained
in the body than in the 5mg dose.
Chromatographic analysis of the urine
samples showed that radioactivity in the
urine from subjects given the low dose was
present only as scission products. No folic
acid was detected in the urine and little or
no 5MeTHF. The major urinary catabolite
was labelled only with 3H and identified as
p-acetamidobenzoyl-L-glutamate. p-Ace-
tamidobenzoate was also detected. The
14C-labelled species was different from that
found earlier, and remains unidentified.
Group IV: Metabolism of 10-formylfolic
acid.-The urinary recovery of the radio-
activity in 24 h after the administration of
[2-14C] + [3',5',7,93H] 10-formylfolic acid
is given in Table V. 49-1% of 3H and
45.2% of14C ofthe dose were recovered in
24 h in the urine. Excretion of radio-
activity in the urine was maximal in the
first period and dropped sharply there-
after. Urine samples were sequentially
chromatographed on DEAE-cellulose and
Sephadex GI5, and this revealed a number
of radioactive components. More than
90% of the urinary radioactivity was
identified as 10-formylfolic acid. The other
metabolites detected in the urine were folic
acid, 5-MeTHF and a very small amount
of 3H-labelled catabolites. More folic acid
was excreted than 5MeTHF, but the total
amount of both did not exceed 3%1 of the
dose (Table VI).
Group V: Effect of 10-formylfolic acid on
folic acid metabolism.-Subjects receiving
oral doses of a mixture of [2-14C] +
[3',5',7,9-3H] folic acid (60 Kg) + 5 mg un-
labelled 10-formylfolic acid excreted in
their urine 17.7% 3H and 16.7% 14C ofthe
labelled dose (Table V). The recovery of3H
and 14C, in individual samples were quite
similar, particularly in the 0-6 and 6-12h
urine samples. Table VI shows the distri-
bution of radiolabelled folate derivatives
in the urine 12 h after the administration
ofthe dose. The major urinary radioactive
product was unmetabolized folic acid.
DISCUSSION
This study shows that orally adminis-
tered folic acid is incorporated into the
reduced folate pool, and confirms the
existence of a breakdown process in man
similar to that elucidated in the rat
(Pheasant et al., 1981). The control
subjects excreted a large proportion ofthe
dose unchanged and, unlike the rat, the
excretion of folic acid continued through-
out the experiment. The folates present
in the urine had a higher 3H/14C ratio than
the administered folic acid (see Table IV),
indicating that the secondary isotope
effect seen in the handling oflabelled folic
acid by the rat (Connor et al., 1980) also
occurs in other species. The same cata-
bolites were identified in the urine of man
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and rat, but the order ofappearance ofthe
two major tritiated species was reversed.
If the radioactivity not recovered in the
urine or faeces is retained in the tissues,
man excretes a higher percentage of the
tissue folates as scission products than the
rat (Table IV). This is consistent with the
suggestion that catabolism proceeds via
oxidative cleavage on the C9-NIO bond
(Murphy et al., 1976; Saleh et al., 1981
since the hepatic NAD/NADH ratio is
higher in man than rat (R. A. Harris,
personal communication).
Patients with malignant disease ex-
creted less radioactivity in the urine.
Intestinal malabsorption of folate is not
usually associated with neoplasia
(Chanarin, 1979) and, by analogy with the
rat, the remaining radioactivity is presum-
ably taken up into tumour tissue (Saleh et
al., 1981). This is supported by the inverse
correlation between the approximate tum-
our mass and urinary radioactivity. These
patients also incorporated more of the
administered folic acid into the reduced
folate pool, as shown by the decreased
excretion offolic acid and the reduced folic
acid/5MeTHF ratio (Table IV), changes
which all become more pronounced in the
more advanced cases. These results reflect
the increased requirement for folate in
malignant disease, arising from presence of
an additional cell mass.
Despite the increased incorporation of
the labelled folate into the reduced folate
pool, lower levels of labelled p-acetamido-
benzoyl-L-glutamate, the catabolite of the
folate polyglutamates, were excreted in
the urine (Table IV). This apparent
decrease in the catabolism of tissue folate
in the presence of a tumour has also been
observed in rats, and it has been suggested
that it is due to the anoxia of solid
tumours, and to the more reducing
conditions prevailing in the cytosol of
tumour cells (Saleh et al., 1981).
Administered 10-formylfolate (5 mg)
was excreted largely unchanged. Approxi-
mately 10% of the dose was excreted as
5MeTHF, and a small proportion was
present as catabolites (Table VI). This
indicates very slow incorporation of 10-
formylfolate into the reduced folate pool.
The presence of folic acid in the urine
suggests that deformylation may precede
reduction. Indeed, the folic acid/5MeTHF
ratio was similar to that after the
administration of folic acid to control
subjects. By analogy with folic acid, some
ofthe dose may have been excreted in the
faeces and possibly a small percentage
retained in the body. The retained radio-
activity may reflect the metabolism ofthat
proportion of the dose that was deformyl-
ated to folic acid. Thus it appears that in
contrast to the rat, 10-formylfolate is
utilized only poorly by man, and is
probably not reduced to any significant
extent in the human body.
Decreasing the dose of folic acid to
I 0 mg or 0 5 mg has been shown to lead to
lower recovery of radioactivity in urine,
with a greater fall in excretion offolic acid
than ofthe other metabolites (Saleh et al.,
1980). In this study a dose about equal to
the daily intake offolate was given (60 ,g)
and the results confirmed the observations
of Pheasant et al. (1979). At this low dose,
little or no folate was excreted and the
only detectable metabolites were scission
products. The low recovery of radio-
activity in the urine probably indicates
that the renal threshold for folates (Johns
et al., 1961) has not been exceeded,
whereas the catabolites appear to have
much lower renalthresholds.
The pattern of urinary metabolites
altered dramatically when the same low
dose of radiolabelled folic acid was given
along with 10-formylfolate (5 mg). A
substantial proportion ofthe folic acid was
rapidly excreted unchanged, and rela-
tively little 5MeTHF or scission products
were formed. 10-Formylfolate is known to
inhibit the reduction of folic acid and
dihydrofolate by mammalian dihydro-
folate reductase (E.C. 1.5.1.3) in vitro
(Bertino et al., 1965; Friedkin et al., 1975;
A. Sahota, personal communication).
These observations suggest that 10-
formylfolate also effectively blocks the
reduction of folic acid in vivo. Hence 10-FOLATE METABOLISM IN MALIGNANT DISEASE 353
formylfolate present in the diet, or formed
in the body by the oxidation of 10-
formyltetrahydrofolate, could have a sig-
nificant effect on the activity of
dihydrofolate reductase.
This work was carried out with thie permission of
the ethical committees of the Central Birmingham
Health District and the University of Aston in
Birmingham.
We are grateful to the Royal Society and the
Cancer Research Campaign for financial support.
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